score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability - High	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.R324L						Investigate Actionability - High	Osimertinib	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	Tagrisso [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2017.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208065s006lbl.pdf	Investigate Actionability - High	Gefitinib	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.R324L (Missense)		135		
Investigate Actionability - High	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.R108K						Investigate Actionability - High	Osimertinib	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	Tagrisso [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2017.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208065s006lbl.pdf	Investigate Actionability - High	Gefitinib	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.R108K (Missense)		135		
Investigate Actionability - High	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.A289V						Investigate Actionability - High	Osimertinib	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	Tagrisso [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2017.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208065s006lbl.pdf	Investigate Actionability - High	Gefitinib	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.A289V (Missense)		135		
Investigate Actionability - High	FDA-Approved	Guideline		Somatic Variant	EGFR	Missense	p.A289T						Investigate Actionability - High	Osimertinib	Targeted therapy	Osimertinib is a kinase inhibitor indicated for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC), as detected by an FDAapproved test, whose disease has progressed on or after EGFR TKI therapy.	Tagrisso [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2017.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208065s006lbl.pdf	Investigate Actionability - High	Gefitinib	Targeted therapy	Second-site mutations within the EGFR kinase domain, such as T790M, are associated with acquired resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										EGFR p.A289T (Missense)		135		
Investigate Actionability - High	Guideline	Guideline		Copy Number	MET	Amplification							Investigate Actionability - High	Crizotinib	Targeted therapy	Crizotinib is an available targeted agent with activity against MET amplifications in metastatic, NSCLC.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 5.2019). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf	Investigate Actionability - High	Gefitinib	Targeted therapy	Amplification of alternative kinases, such as MET, may suggest resistance to EGFR TKIs.	National Comprehensive Cancer Network. Non-Small Cell Lung Cancer NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf										MET Amplification		135		
Investigate Actionability - High	Clinical evidence			Copy Number	EGFR	Amplification							Investigate Actionability - High	Gefitinib	Targeted therapy	Amplification and mutation of EGFR was associated with better clinical outcomes in a trial of 66 non-small cell lung cancer patients who had experienced relapse after surgery.	Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005;23(28):6829-37.	https://doi.org/10.1200/JCO.2005.01.0793																EGFR Amplification		135		
Investigate Actionability - High	Preclinical			Copy Number	CDKN2A	Deletion							Investigate Actionability - High	EPZ015666	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214																CDKN2A Deletion		135		
